TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck.

ABSTRACT:

Objectives

The aim of this study was to confirm the efficacy of the ERBITAX scheme (paclitaxel 80 mg/m² weekly and cetuximab 400 mg/m² loading dose, and then 250 mg/m² weekly) as first-line treatment for patients with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) who are medically unfit for cisplatin-based (PT) chemotherapy.

Materials and methods

This retrospective, non-interventional study involved 16 centers in Spain. Inclusion criteria were to have started receiving ERBITAX regimen from January 2012 to December 2018; histologically confirmed SCCHN including oral cavity, oropharynx, hypopharynx, and larynx; age ≥18 years; and platinum (PT) chemotherapy ineligibility due to performance status, comorbidities, high

SUBMITTER: Rubio-Casadevall J 

PROVIDER: S-EPMC10432957 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature